Molecular imaging and targeted therapies

Biochemical Pharmacology

Volumn 80, Issue 5, 2010, Pages 731-738

  Morse, David L ^a   Gillies, Robert J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Biomarker; Extracellular; Intracellular; Target; Targeted therapy

Indexed keywords

ALPHA METHYL TRYPTOPHAN; BIOLOGICAL MARKER; MISONIDAZOLE; TRYPTOPHAN; UNCLASSIFIED DRUG;

CANCER RESEARCH; DRUG TARGETING; GENE EXPRESSION; GENE SEQUENCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REPORTER GENE; REVIEW;

GENES, REPORTER; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954216770     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.04.011     Document Type: Review

References (96)

1. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003, 21:2237-2246.
2. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J Am Med Assoc 2003, 290:2149-2158.
3. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004, 22:777-784.
4. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004, 22:785-794.
5. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med 2004, 350:2129-2139.
6. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (New York, NY) 2004, 304:1497-1500.
7. Zhao B., Schwartz L.H., Moskowitz C.S., Ginsberg M.S., Rizvi N.A., Kris M.G. Lung cancer: computerized quantification of tumor response-initial results. Radiology 2006, 241:892-898.
8. Arthur J., Atkinson J., Wayne M.D., Colburn A., Victor P., DeGruttola G., et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
9. Tan D.S.W., Thomas G.V., Garrett M.D., Banerji U., de Bono J.S., Kaye S.B., et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 2009, 15:406-420.
10. Tagliabue E, Balsari A, Campiglio M, Pupa SM. HER2 as a target for breast cancer therapy. Expert Opin Biol Ther 2010;10:711-24.
11. Wei B.-R., Hoover S.B., Ross M.M., Zhou W., Meani F., Edwards J.B., et al. Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients. PLoS ONE [Electronic Resource] 2009, 4:e7670.
12. Lausted C., Hu Z., Hood L. Quantitative serum proteomics from surface plasmon resonance imaging. Mol Cell Proteomics 2008, 7:2464-2474.
13. Leman E.S., Getzenberg R.H. Biomarkers for prostate cancer. J Cell Biochem 2009, 108:3-9.
14. Rubin M.A. Using molecular markers to predict outcome. J Urol 2004, 172:S18-S21. discussion S-2.
15. Ross J.S., Schenkein D.P., Kashala O., Linette G.P., Stec J., Symmans W.F., et al. Pharmacogenomics. Adv Anat Pathol 2004, 11:211-220.
16. Wagner J.A. Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 2002, 18:41-46.
17. Lesko L.J., Atkinson A.J. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001, 41:347-366.
18. Stephen R.M., Gillies R.J. Promise and progress for functional and molecular imaging of response to targeted therapies. Pharm Res 2007, 24:1172-1185.
19. Schwartz L.H., Bogaerts J., Ford R., Shankar L., Therasse P., Gwyther S., et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer 2009, 45:261-267.
20. Curran S.D., Muellner A.U., Schwartz L.H. Imaging response assessment in oncology. Cancer Imaging 2006, 6:S126-S130.
21. Birchard K.R., Hoang J.K., Herndon J.E., Patz E.F. Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. Cancer 2009, 115:581-586.
22. Wilmes L.J., Pallavicini M.G., Fleming L.M., Gibbs J., Wang D., Li K.-L., et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 2007, 25:319-327.
23. Rose C.J., Mills S.J., O'Connor J.P.B., Buonaccorsi G.A., Roberts C., Watson Y., et al. Quantifying spatial heterogeneity in dynamic contrast-enhanced MRI parameter maps. Magn Reson Med 2009, 62:488-499.
24. Patterson D.M., Padhani A.R., Collins D.J. Technology insight: water diffusion MRI-a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol 2008, 5:220-233.
25. O'Connor J.P.B., Naish J.H., Parker G.J.M., Waterton J.C., Watson Y., Jayson G.C., et al. Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumors. Int J Radiat Oncol Biol Phys 2009, 75:1209-1215.
26. Padhani A.R., Krohn K.A., Lewis J.S., Alber M. Imaging oxygenation of human tumours. Eur Radiol 2007, 17:861-872.
27. Vavere A.L., Biddlecombe G.B., Spees W.M., Garbow J.R., Wijesinghe D., Andreev O.A., et al. A novel technology for the imaging of acidic prostate tumors by positron emission tomography. Cancer Res 2009, 69:4510-4516.
28. Gambhir S.S., Czernin J., Schwimmer J., Silverman D.H., Coleman R.E., Phelps M.E. A tabulated summary of the FDG PET literature. J Nucl Med 2001, 42:1S-93S.
29. Margolis D.J., Hoffman J.M., Herfkens R.J., Jeffrey R.B., Quon A., Gambhir S.S. Molecular imaging techniques in body imaging. Radiology 2007, 245:333-356.
30. Alford R., Ogawa M., Choyke P.L., Kobayashi H. Molecular probes for the in vivo imaging of cancer. Mol Biosyst 2009, 5:1279-1291.
31. Zhu W., Okollie B., Bhujwalla Z.M., Artemov D. PAMAM dendrimer-based contrast agents for MR imaging of Her-2/neu receptors by a three-step pretargeting approach. Magn Reson Med 2008, 59:679-685.
32. Gillies R.J., Morse D.L. In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng 2005, 7:287-326.
33. Golman K., Zandt R.I., Lerche M., Pehrson R., Ardenkjaer-Larsen J.H. Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res 2006, 66:10855-10860.
34. Witney T.H., Kettunen M.I., Day S.E., Hu D.E., Neves A.A., Gallagher F.A., et al. A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized (13)C-labeled pyruvate utilization as methods for detecting tumor response to treatment. Neoplasia (New York, NY) 2009, 11:574-582. [1 p following 82].
35. Matsumoto S., Yasui H., Batra S., Kinoshita Y., Bernardo M., Munasinghe J.P., et al. Simultaneous imaging of tumor oxygenation and microvascular permeability using Overhauser enhanced MRI. Proc Natl Acad Sci USA 2009, 106:17898-17903.
36. Keshari K.R., Wilson D.M., Chen A.P., Bok R., Larson P.E., Hu S., et al. Hyperpolarized [2-13C]-fructose: a hemiketal DNP substrate for in vivo metabolic imaging. J Am Chem Soc 2009, 131:17591-17596.
37. Karlsson M, Jensen PR, In't Zandt R, Gisselsson A, Hansson G, Duus JO, et al. Imaging of branched chain amino acid metabolism in tumors with hyperpolarized (13)C ketoisocaproate. Int J Cancer 2009 Dec 3 [Epub ahead of print].
38. Gallagher F.A., Kettunen M.I., Hu D.E., Jensen P.R., Zandt R.I., Karlsson M., et al. Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors. Proc Natl Acad Sci USA 2009, 106:19801-19806.
39. Gallagher F.A., Kettunen M.I., Day S.E., Hu D.E., Ardenkjaer-Larsen J.H., Zandt R., et al. Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature 2008, 453:940-943.
40. Gallagher F.A., Kettunen M.I., Day S.E., Lerche M., Brindle K.M. 13C MR spectroscopy measurements of glutaminase activity in human hepatocellular carcinoma cells using hyperpolarized 13C-labeled glutamine. Magn Reson Med 2008, 60:253-257.
41. Banerjee H.N., Verma M. Application of nanotechnology in cancer. Technol Cancer Res Treat 2008, 7:149-154.
42. Longmire M., Choyke P.L., Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (London, England) 2008, 3:703-717.
43. Louie A. Multimodality imaging probes: Design and challenges. Chem Rev 2010 Mar 15 [Epub ahead of print].
44. Bae Y., Nishiyama N., Kataoka K. In vivo antitumor activity of the folate-conjugated pH-sensitive polymeric micelle selectively releasing adriamycin in the intracellular acidic compartments. Bioconjugate Chem 2007, 18:1131-1139.
45. Munn D.H., Zhou M., Attwood J.T., Bondarev I., Conway S.J., Marshall B., et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science (New York, NY) 1998, 281:1191-1193.
46. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003, 9:1269-1274.
47. Friberg M., Jennings R., Alsarraj M., Dessureault S., Cantor A., Extermann M., et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 2002, 101:151-155.
48. Mellor A.L., Keskin D.B., Johnson T., Chandler P., Munn D.H. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol 2002, 168:3771-3776.
49. Mellor A.L., Munn D., Chandler P., Keskin D., Johnson T., Marshall B., et al. Tryptophan catabolism and T cell responses. Adv Exp Med Biol 2003, 527:27-35.
50. Muller A.J., DuHadaway J.B., Donover P.S., Sutanto-Ward E., Prendergast G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005, 11:312-319.
51. Munn D.H. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 2006, 18:220-225.
52. Munn D.H., Shafizadeh E., Attwood J.T., Bondarev I., Pashine A., Mellor A.L. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999, 189:1363-1372.
53. Astigiano S., Morandi B., Costa R., Mastracci L., D'Agostino A., Ratto G.B., et al. Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. Neoplasia (New York, NY) 2005, 7:390-396.
54. Yasui H., Takai K., Yoshida R., Hayaishi O. Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients. Proc Natl Acad Sci USA 1986, 83:6622-6626.
55. Brandacher G., Perathoner A., Ladurner R., Schneeberger S., Obrist P., Winkler C., et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006, 12:1144-1151.
56. Sakurai K., Amano S., Enomoto K., Kashio M., Saito Y., Sakamoto A., et al. Study of indoleamine 2,3-dioxygenase expression in patients with breast cancer. Gan to kagaku ryoho 2005, 32:1546-1549.
57. Ishio T., Goto S., Tahara K., Tone S., Kawano K., Kitano S. Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J Gastroenterol Hepatol 2004, 19:319-326.
58. Okamoto A., Nikaido T., Ochiai K., Takakura S., Saito M., Aoki Y., et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 2005, 11:6030-6039.
59. Juhasz C., Chugani D.C., Muzik O., Wu D., Sloan A.E., Barger G., et al. In vivo uptake and metabolism of alpha-[11C]methyl-l-tryptophan in human brain tumors. J Cereb Blood Flow Metab 2006, 26:345-357.
60. Juhasz C., Muzik O., Lu X., Jahania M.S., Soubani A.O., Khalaf M., et al. Quantification of tryptophan transport and metabolism in lung tumors using PET. J Nucl Med 2009, 50:356-363.
61. Rasey J.S., Koh W.J., Grierson J.R., Grunbaum Z., Krohn K.A. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989, 17:985-991.
62. Lee S.T., Scott A.M. Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. Semin Nucl Med 2007, 37:451-461.
63. Rischin D., Hicks R.J., Fisher R., Binns D., Corry J., Porceddu S., et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006, 24:2098-2104.
64. Abdel Razek AA, Gaballa G, Denewer A, Tawakol I. Diffusion weighted MR imaging of the breast. Acad Radiol 2010;17:382-6.
65. Chawla S., Kim S., Wang S., Poptani H. Diffusion-weighted imaging in head and neck cancers. Future Oncol 2009, 5:959-975.
66. Niwa T., Ueno M., Ohkawa S., Yoshida T., Doiuchi T., Ito K., et al. Advanced pancreatic cancer: the use of the apparent diffusion coefficient to predict response to chemotherapy. Br J Radiol 2009, 82:28-34.
67. Pope W.B., Kim H.J., Huo J., Alger J., Brown M.S., Gjertson D., et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009, 252:182-189.
68. Korpal M., Yan J., Lu X., Xu S., Lerit D.A., Kang Y. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med 2009, 15:960-966.
69. Shu X., Royant A., Lin M.Z., Aguilera T.A., Lev-Ram V., Steinbach P.A., et al. Mammalian expression of infrared fluorescent proteins engineered from a bacterial phytochrome. Science (New York, NY) 2009, 324:804-807.
70. Maeda H., Bharate G.Y., Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 2009, 71:409-419.
71. Gullotti E., Yeo Y. Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm 2009, 6:1041-1051.
72. Leiner T., Kucharczyk W. Special issue: nephrogenic systemic fibrosis. J Magn Reson Imaging 2009, 30:1233-1235.
73. Aime S., Barge A., Cabella C., Crich S.G., Gianolio E. Targeting cells with MR imaging probes based on paramagnetic Gd(III) chelates. Curr Pharm Biotechnol 2004, 5:509-518.
74. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev 2010;10:9-22.
75. Schnell O., Krebs B., Carlsen J., Miederer I., Goetz C., Goldbrunner R.H., et al. Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro-oncology 2009, 11:861-870.
76. Liu Z., Niu G., Shi J., Liu S., Wang F., Liu S., et al. (68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging 2009, 36:947-957.
77. Edwards W.B., Akers W.J., Ye Y., Cheney P.P., Bloch S., Xu B., et al. Multimodal imaging of integrin receptor-positive tumors by bioluminescence, fluorescence, gamma scintigraphy, and single-photon emission computed tomography using a cyclic RGD peptide labeled with a near-infrared fluorescent dye and a radionuclide. Mol Imaging 2009, 8:101-110.
78. Wu Y., Cai W., Chen X. Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. Mol Imaging Biol 2006, 8:226-236.
79. Huo T, Du X, Zhang S, Liu X, Li X. Gd-EDDA/HYNIC-RGD as an MR molecular probe imaging integrin alphanubeta3 receptor-expressed tumor-MR molecular imaging of angiogenesis. Eur J Radiol 2010;73:420-7.
80. Wang Y., Wang X., Zhang Y., Yang S., Wang J., Zhang X., et al. RGD-modified polymeric micelles as potential carriers for targeted delivery to integrin-overexpressing tumor vasculature and tumor cells. J Drug Target 2009, 17:459-467.
81. Chen X., Plasencia C., Hou Y., Neamati N. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem 2005, 48:1098-1106.
82. Kossodo S, ickarski M, Lin SA, Gleason A, Gaspar R, Buono C, et al. Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT). Mol Imaging Biol 2009 Dec 4 [Epub ahead of print].
83. Bodei L., Cremonesi M., Zoboli S., Grana C., Bartolomei M., Rocca P., et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med 2003, 30:207-216.
84. Corot C., Robert P., Lancelot E., Prigent P., Ballet S., Guilbert I., et al. Tumor imaging using P866, a high-relaxivity gadolinium chelate designed for folate receptor targeting. Magn Reson Med 2008, 60:1337-1346.
85. Sega E.I., Low P.S. Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev 2008, 27:655-664.
86. Bettio A., Honer M., Muller C., Bruhlmeier M., Muller U., Schibli R., et al. Synthesis and preclinical evaluation of a folic acid derivative labeled with 18F for PET imaging of folate receptor-positive tumors. J Nucl Med 2006, 47:1153-1160.
87. Ronald J.A., Chen J.W., Chen Y., Hamilton A.M., Rodriguez E., Reynolds F., et al. Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. Circulation 2009, 120:592-599.
88. Querol M., Chen J.W., Bogdanov A.A. A paramagnetic contrast agent with myeloperoxidase-sensing properties. Organ Biomol Chem 2006, 4:1887-1895.
89. Shiftan L., Neeman M. Kinetic analysis of hyaluronidase activity using a bioactive MRI contrast agent. Contrast Media Mol Imaging 2006, 1:106-112.
90. Weissleder R., Tung C.H., Mahmood U., Bogdanov A. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 1999, 17:375-378.
91. McElroy M., Kaushal S., Luiken G.A., Talamini M.A., Moossa A.R., Hoffman R.M., et al. Imaging of primary and metastatic pancreatic cancer using a fluorophore-conjugated anti-CA19-9 antibody for surgical navigation. World J Surg 2008, 32:1057-1066.
92. Fang X., Balgley B.M., Lee C.S. Recent advances in capillary electrophoresis-based proteomic techniques for biomarker discovery. Electrophoresis 2009, 30:3998-4007.
93. Robey I.F., Stephen R.M., Brown K.S., Baggett B.K., Gatenby R.A., Gillies R.J. Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia (New York, NY) 2008, 10:745-756.
94. Korc M. Pancreatic cancer-associated stroma production. Am J Surg 2007, 194:S84-S86.
95. Mahadevan D., Von Hoff D.D. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007, 6:1186-1197.
96. Zischek C., Niess H., Ischenko I., Conrad C., Huss R., Jauch K.W., et al. Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Ann Surg 2009, 250:747-753.